1 / 30

Starting ART in the Context of Opportunistic Infections

Starting ART in the Context of Opportunistic Infections. HAIVN Harvard Medical School AIDS Initiative in Vietnam. Learning Objectives. By the end of this session, participants should be able to: Explain the best time and clinical conditions that an acute OI patient can start ART

benderj
Download Presentation

Starting ART in the Context of Opportunistic Infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam

  2. Learning Objectives By the end of this session, participants should be able to: • Explain the best time and clinical conditions that an acute OI patient can start ART • Describe how to start ART in the context of acute OIs

  3. Starting ARV in the Context of OIs:Advantages and Disadvantages Advantages • Recovery of immune system • Mortality reduction • Treatment of OI • Prevention of other OI and complications due to HIV disease Disadvantages • Risk of IRIS • Drug interactions • Drug adverse effects • Number of pills: adherence It’s never an emergency to start ART

  4. General Principles (1) • Little data exist on best time to start ART when a patient is being treated for an OI • Clinical judgment must be used • Before starting ARV, patient should be: • Responding to OI therapy, clinically stable • Tolerating OI drugs with no side effects

  5. General Principles (2) • It’s important to know drug-drug interactions of all medications before they are prescribed • If the patient is already on ART, do not stop • Continue ART and start OI treatment • Change ART regimen if necessary to avoid interactions with OI drugs

  6. With Which OIs do you Need to Start ARVs Right Away?

  7. OIs that Require ARVs to Resolve • Diarrheal agents • Kaposi Sarcoma • Progressive Multifocal Leukoencephalopathy (PML) • Non-infectious causes: • Malignancy • Autoimmune conditions • Skin conditions In these cases, ARVs should be started as soon as possible

  8. With Which OIs Should You Delay the Start of ART?

  9. OIs With Which ART Should Be Delayed • Tuberculosis and other mycobacterial infections • Cerebral toxoplasmosis • Pneumocystis Jiroveci Pneumonia (PCP) • Cryptococcosis • Penicillium marneffei • Other fungal infections

  10. Starting ARVs in the Context of an Acute OI

  11. Principles for Starting ARVs in the Context of an Acute OI General Principle: Treat the OI first

  12. ART and Tuberculosis

  13. Antiretroviral Therapy and TB: Early vs. Late ARV (1) • TB is associated with increased HIV disease progression • Benefits of early ARV: • Reduction in HIV viral load and slowing of HIV disease progression • Reduction in risk of developing other OIs • Prevention of new AIDS defining illnesses and reduction in mortality

  14. Antiretroviral Therapy and TB: Early vs. Late ARV (2) • However, there are also risks to starting ARVs early such as: • Drug toxicity/intolerance • hepatotoxicity • peripheral neuropathy from INH & D4T • drug allergy or hypersensitivity • Drug interactions (RIF & ARV) • Pill burden (>15 pills/day) • IRIS • Patient may be ready for ARV or not

  15. HIV and TB: When to Start ARVs? If CD4 Available Guidelines for Diagnosis and Treatment of HIV/AIDS, MOH Vietnam. 2009. * If patient is at clinical stage 4, provide ART immediately after the tolerance of TB drugs (between 2-8 weeks)

  16. Which ARV to Start? • If patient is already on ART, do not stop • If patient is on RIF and EFV is available, substitute EFV for NVP • If EFV is not available or if patient cannot take EFV, then: • Use NVP with TB treatment • Second Line ARV: • Cannot take PI with RIF due to  PI drug levels • Refer to specialty center for treatment

  17. Case Study, Lan (1) • Lan, a 29 year old woman is referred to the HIV OPC by the district TB center • Just diagnosed with pulmonary TB and also had a positive HIV test. • Has been taking TB drugs (RHEZ) for 2 weeks • TB doctor has referred her to your OPC for ART • What factors should you consider when deciding when to start ART for this patient?

  18. Case Study, Lan (2) • Further information: • The CD4 cell count is 25 cells/mm3. • Other lab tests are within normal limits • She has been tolerating the TB drugs without difficulty and with good adherence. • She lives close by and is willing to return to the OPC frequently for close monitoring • When would you recommend she start ART? • What ART regimen would you recommend?

  19. ART and Cryptococcus Meningitis

  20. Timing of ART in Cryptococcal Meningitis (CM) (1) Optimal time to start ART in patients with CM is not clear • There are conflicting data from studies examining the risk of mortality from IRIS associated with a diagnosis of CM • Increased intracranial pressure related to IRIS may result in higher rates of morbidity and mortality

  21. Timing of ART in Cryptococcal Meningitis (2) General Recommendations • Defer starting ART until patients are clinically stable on anti-fungal treatment • Usually occurs between 2-10 weeks after starting cryptococcal treatment • Regardless of when starting ART, aggressive management of elevated intracranial pressure is vital

  22. Case Study, Tuan Anh (1) • Tuan Anh, a 30 year old man with HIV presents to the hospital because of 4 days of fever, severe headache, and blurry vision. • His CD4 count is 70. • A lumbar puncture is performed. • WBC count 20 cells/cc3, with 90% lymphocytes. • Protein 0,85g/l • Glucose normal • India Ink stain is positive for many Cryptococcus yeast forms.

  23. Case Study, Tuan Anh (2) • Tuan Anh is started on treatment for cryptococcal meningitis • His treatment plan includes: • Management of intracranial pressure • Amphotericin B at 0.7mg/kg/day for 2 weeks • Fluconazole 900 mg/day for another 8 weeks • Secondary prophylaxis with fluconazole 150 mg/day • At which point during this treatment course would you start ARV?

  24. ART in the Context of Other Acute OIs

  25. Some OI drugs may have decreased blood levels due to increased metabolism: OI Drug Interactions (1)

  26. Some OI drugs may have decreased blood levels due to decreased absorption: OI Drug Interactions (2)

  27. Case Study, Phuong (1) • Phuong, a 25 year old woman with HIV comes to the OPC with recurrent fever and skin lesions • 2 months ago she was diagnosed with penicilliosis • She improved quickly after treatment with Itraconazole 200 mg twice daily

  28. Case Study, Phuong (2) • Now, however, symptoms have returned • 4 weeks ago she started on ART (D4T, 3TC, NVP) • 2 weeks ago she decreased her Itraconazole dose to 200 mg daily for maintenance therapy • What are possible explanations for Phuong’s recurrent penicilliosis symptoms? • How might you manage this situation?

  29. Key Points • For patient with an acute OI, start ART when patient is clinically stable and tolerating OI treatment • Patients with more advanced immunosuppression (CD4<250) should be started on ART as soon as possible (between 2-8 weeks) • Clinicians should be aware of potential interactions between OI drugs and ARV

  30. Thank You Questions?

More Related